Patents by Inventor Ruocong ZHAO

Ruocong ZHAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ScFv amino acid sequence, chimeric antigen receptor containing same and application thereof
    Patent number: 11713348
    Abstract: The present disclosure relates to a scFv amino acid sequence capable of recognizing CD19 antigen and a nucleotide sequence encoding the same, and also relates to a chimeric antigen receptor, a nucleic acid encoding the same and a cell expressing the same, and their uses in the manufacture of a medicament for treating tumors. The chimeric antigen receptor of the present disclosure comprises at least one extracellular domain, an optional transmembrane domain and at least one intracellular costimulatory signaling domain, wherein the extracellular domain comprises a CD19 antigen-recognizing and binding domain. The chimeric antigen receptor of the present disclosure has been humanized, resulting in a longer survival period in vivo, and a corresponding extended complete remission period in patients.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: August 1, 2023
    Assignee: GUANGDONG ZHAOTAI INVIVO BIOMEDICINE CO., LTD
    Inventors: Peng Li, Ruocong Zhao, Zhaoyang Tang, Le Qin, Yuanbin Cui, Simiao Lin, Yao Yao
  • NOVEL SCFV AMINO ACID SEQUENCE, CHIMERIC ANTIGEN RECEPTOR CONTAINING SAME AND APPLICATION THEREOF
    Publication number: 20210238253
    Abstract: The present disclosure relates to a scFv amino acid sequence capable of recognizing CD19 antigen and a nucleotide sequence encoding the same, and also relates to a chimeric antigen receptor, a nucleic acid encoding the same and a cell expressing the same, and their uses in the manufacture of a medicament for treating tumors. The chimeric antigen receptor of the present disclosure comprises at least one extracellular domain, an optional transmembrane domain and at least one intracellular costimulatory signaling domain, wherein the extracellular domain comprises a CD19 antigen-recognizing and binding domain. The chimeric antigen receptor of the present disclosure has been humanized, resulting in a longer survival period in vivo, and a corresponding extended complete remission period in patients.
    Type: Application
    Filed: March 8, 2019
    Publication date: August 5, 2021
    Inventors: Peng LI, Ruocong ZHAO, Zhaoyang TANG, Le QIN, Yuanbin CUI, Simiao LIN, Yao YAO